To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Continuous infusion of bupivacaine following TKA does not improve morphine consumption

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
May 2013

Continuous infusion of bupivacaine following TKA does not improve morphine consumption

Vol: 2| Issue: 4| Number:70| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Continuous infusion of bupivacaine following total knee arthroplasty: a randomized control trial pilot study

J Arthroplasty. 2013 Mar;28(3):479-84. doi: 10.1016/j.arth.2012.07.016. Epub 2012 Nov 2

Contributing Authors:
D Williams D Petruccelli J Paul L Piccirillo M Winemaker J de Beer

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

67 patients were randomized in this pilot study to evaluate the efficacy of a 48h continuous local infiltration of bupivacaine on reducing morphine consumption following total knee arthroplasty (TKA). Patients received either local infiltration of intra-articular bupivacaine (0.5% at 2 cc/h) or placebo (0.5% saline at 2 cc/h) and were assessed over the first 48 hours and at 1 year. Results reveale...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue